Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
What is your approach to management of severe osteoporosis in patients with advanced kidney disease?
Do you consider anabolic agents and if so, what is your approach to monitoring?
Related Questions
Would you consider teriparatide use in a patient with prior radiation therapy, given that the black box warning regarding osteosarcoma risk has been removed by the FDA?
Is it safe to give an anabolic agent for osteoporosis without following up with an anti-resorptive agent?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
Is elevated bone specific alkaline phosphatase an absolute contraindication to teriparatide?
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Is it safe to continue administering Prolia per schedule for osteoporosis treatment shortly after a patient has undergone extensive spinal surgery?
How long after parathyroidectomy (for parathyroid adenoma with hyperparathyroidism) do you wait before initiating romosuzumab in an older patient with osteoporosis and very high fracture risk?
Would you use anabolic agents (romosozumab or PTH analogues) for osteoporosis treatment in patients with CKD?
Can anabolic agents be used in a patient with history of radioactive iodine treatment for hyperthyroidism?
What is your approach to managing osteoporosis in patients with end stage kidney disease?